Jeff BoyleROCKVILLE, MARYLAND, July 6, 2020 The Board of Directors of BioHealth Innovation, Inc. (BHI) unanimously approved the appointment of Jeff Boyle as a new board member. Jeff Boyle is the President of Ellume USA LLC and leads the team establishing the manufacturing operation and commercial headquarters in Maryland; and is responsible for all aspects of the North American business operation. Jeff has previously held leadership positions at CSL, Cellestis, and most recently with QIAGEN as a Global Franchise Head.

 “I am pleased to welcome Jeff to our Board of Directors,” said Richard Bendis, BHI President, and CEO. “Jeff brings decades of experience to our Board, and we’re thrilled to have him, and Ellume USA LLC has part of the BioHealth Capital Region.”

Jeff Boyle has over 25 years of experience in immunology research, assay development, and commercialization. He has published more than 30 papers and has received several high-level academic awards. For the last decade Jeff has had an in vitro diagnostic focus for providing insights into unmet medical needs in infectious diseases and transplantation. He is an inventor on several patents and has led the teams necessary for taking diagnostics from concept through to registration and global commercialization.

“Ellume is committed to be establishing a long-term business in the BioHealth Capital Region.  In the short term, we’re focused on helping the U.S. emerge from this pandemic and in parallel, building local manufacturing capacity to be better prepared for the next one.,” said Jeff Boyle, President Ellume USA LLC. “I look forward to joining the BHI Board as Ellume’s representative and advancing the synergistic aims of BHI in fostering investment, jobs growth, talent retention and furthering overall firepower in the region.”

About BioHealth Innovation, Inc.

BioHealth Innovation, Inc. (BHI) is a public-private nonprofit organization focused on accelerating biohealth (therapeutic, diagnostic, medtech, and health IT) commercialization in the BioHealth Capital Region (Maryland, DC and Virginia). BHI’s team of expert Entrepreneurs-in-Residence, in-house venture analysts, and other professional staff work in the region to:

  • Facilitate technology commercialization,
  • Raise the profile of the industry cluster and individual organizations,
  • Increase access to capital for early stage and growing companies, and
  • Expand the pool of talent with commercially relevant experience.

BHI’s early stage company support includes market research and commercialization plan development; non-dilutive funding application assistance; a jobs board;  event calendar; and introductions to investors, strategic partners, business advisors, and potential clients. BHI also manages wet lab space and provides referrals to other space for early stage companies, offers soft-landing support for international companies, and works with partners to co-host the annual BioHealth Capital Region Forum and an annual BioHealth Capital Region investor partnering conference. For more information: